PTC THERAPEUTICS, INC. - 10-Q Filing
PTC Therapeutics reports Q3 2026 financial results including collaboration revenue from Novartis and updates to intangible asset valuations.
Tickers: $PTCT
PTC Therapeutics reports Q3 2026 financial results including collaboration revenue from Novartis and updates to intangible asset valuations.
Tickers: $PTCT